Latest Press Releases & News

Alessa Therapeutics announced the enrollment of the first patient in the company’s Enolen® clinical study at the National Cancer Institute (NCI), part of the National…

Alessa Therapeutics announced today the appointment of Cam Gallagher as President and Chief Executive Officer, effective immediately.

Alessa Therapeutics announced the closing of a $15M seed financing led by Mission BioCapital joined by Johnson & Johnson (through its corporate venture capital organization,…

Alessa Therapeutics Inc. today announced that they will be presenting a podium poster at the 2024 annual American Association of Urology (AUA) annual meeting in…

Alessa Therapeutics Inc. today announced that they will be presenting a poster at the 2024 annual European Association of Urology (EAU) annual meeting in Paris,…

Alessa Therapeutics announced the enrollment of the first two men with prostate cancer in the company’s Biolen+RT clinical study. Biolen+RT (NCT 04943536) is a Phase…

Alessa Therapeutics announced that it has entered into a research collaboration agreement with an affiliate of Janssen Research & Development, LLC. This agreement was facilitated by Johnson…

Alessa Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) for Biolen®. Alessa, in collaboration with…

Alessa Therapeutics announced the enrollment of the first patient in the company’s Biolen-PC clinical study in Australia. Biolen-PC (NCT 04284761) is a first-in-man study evaluating…

Alessa Therapeutics announced the enrollment of the first patient in the company’s Biolen-PC clinical study. Biolen-PC is a first-in-man study evaluating safety and patient tolerance…